News

This new plan will accelerate the timing of the trial’s efficacy and safety data to mid-2009, the company said. The previously announced interim analysis based on the first

In this analysis, the study met its primary endpoint of absolute change in total lean body mass (muscle) compared to placebo and the secondary endpoint of muscle function

The Luxtec MLX 300W Xenon light source system has received 510(k) clearance from the FDA to be marketed in the US. The Luxtec MLX 300W Xenon light source,

Under the terms of the agreement, TorreyPines will receive an upfront payment and is eligible to receive milestone and royalty payments for future products based on the licensed

Dr Jacob joined Antares’s board in January 2007 bringing over 29 years of pharmaceutical industry experience including having founded InKine Pharmaceutical Company in 1997 and served as chairman

The alliance will focus on supporting Infinity’s pipeline of novel, small molecule oncology drug candidates, including IPI-926, a potent inhibitor of the Hedgehog pathway, which is being evaluated

This marketing application is being made for the interventional use of Voraxaze for the rapid and sustained reduction of methotrexate (MTX) in patients who have toxic MTX levels

This reduction in workforce will affect positions in company locations including Pennsylvania, New York and other geographies. Dave DiGiacinto, president and COO, said: “We have taken this difficult,

Subject to securing an agreement with the FDA, Duska intends to initiate a single, prospective, double-blind, placebo-controlled and randomized Phase III clinical trial with its lead product ATPace.